ClinVar Miner

Submissions for variant NM_000098.3(CPT2):c.691C>T (p.Arg231Trp)

gnomAD frequency: 0.00004  dbSNP: rs373638740
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000674663 SCV000800042 uncertain significance Carnitine palmitoyl transferase II deficiency, severe infantile form 2018-05-18 criteria provided, single submitter clinical testing
Invitae RCV000796802 SCV000936330 likely pathogenic Carnitine palmitoyltransferase II deficiency 2024-01-30 criteria provided, single submitter clinical testing This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 231 of the CPT2 protein (p.Arg231Trp). This variant is present in population databases (rs373638740, gnomAD 0.006%). This missense change has been observed in individuals with carnitine palmitoyltransferase II deficiency and/or CPT2-related conditions (PMID: 16996287, 24398345, 24602495, 30455135). ClinVar contains an entry for this variant (Variation ID: 203661). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CPT2 protein function with a positive predictive value of 80%. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
CeGaT Center for Human Genetics Tuebingen RCV001092683 SCV001249307 pathogenic not provided 2016-10-01 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV001092683 SCV001715288 uncertain significance not provided 2021-06-01 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV003230439 SCV003928783 uncertain significance not specified 2023-04-12 criteria provided, single submitter clinical testing Variant summary: CPT2 c.691C>T (p.Arg231Trp) results in a non-conservative amino acid change located in the Choline/carnitine acyltransferase domain of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 250840 control chromosomes. c.691C>T has been reported in the literature in individuals affected with Carnitine Palmitoyltransferase II Deficiency. These data indicate that the variant may be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (VUS n=4, pathogenic n=1). Based on the evidence outlined above, the variant was classified as VUS-possibly pathogenic.
Baylor Genetics RCV003474940 SCV004211033 pathogenic Encephalopathy, acute, infection-induced, susceptibility to, 4 2023-10-12 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV003927721 SCV004741138 uncertain significance CPT2-related condition 2024-02-14 criteria provided, single submitter clinical testing The CPT2 c.691C>T variant is predicted to result in the amino acid substitution p.Arg231Trp. This variant has been reported with a second CPT2 variant in individuals with carnitine palmitoyltransferase II deficiency; however, pathogenicity was not established (Isackson et al. 2006. PubMed ID: 16996287; Table 4, Joshi et al. 2013. PubMed ID: 24398345; Table 1, Lehmann and Zierz. 2014. PubMed ID: 24602495). This variant is reported in 0.0062% of alleles in individuals of European (non-Finnish) descent in gnomAD. Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.
Natera, Inc. RCV000796802 SCV001454230 uncertain significance Carnitine palmitoyltransferase II deficiency 2020-09-16 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.